The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report. Journal Abstract - Guideline Central

The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report.

Published: 2026

Authors

, , ,

Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality, with resistance to systemic therapies limiting outcomes. Arginine depletion with ADI-PEG 20 may enhance the efficacy of tyrosine kinase inhibitors (TKIs) such as lenvatinib.

Keywords: ADI-PEG 20, Hepatocellular carcinoma, Lenvatinib, resistance

Source

In vivo (Athens, Greece)

Publication Type

Journal Article

Language

English

PubMed ID

42379775

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.